Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present GT Biopharma Inc. (OTC: GTBP).

Full DD Report for GTBP

You must become a subscriber to view this report.



Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-120.820.8350.860.7871,906
2018-12-110.910.8350.930.78156,470
2018-12-100.960.900.970.88146,110
2018-12-070.980.9460.980.8875144,947
2018-12-060.960.981.000.95201,469

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-1180,310156,47051.3261Short
2018-12-1069,462146,11047.5409Short
2018-12-0792,191144,94763.6032Short
2018-12-0678,126196,56939.7448Short
2018-12-0495,588208,49845.8460Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on GTBP.


About GT Biopharma Inc. (OTC: GTBP)

Logo for GT Biopharma Inc. (OTC: GTBP)

At GT Biopharma, Inc., we are developing innovative drugs for the treatment of cancers and central nervous system diseases.

 

 

 

Current Management

  • Shawn M. Cross / CEO
  • Kathleen ClarenceSmith / CEO
    • Dr. ClarenceSmith founded GTP in . Prior to founding GTP, she cofounded Chase Pharmaceuticals Corporation in Washington D.C. and served as Chairman of the company s Board from to . Chase Pharmaceuticals was acquired by Allergan, PLC AGN in for million together with potential addition payments of million based upon regulatory and commercial milestones. Dr. ClarenceSmith also held executive management positions with Sanofi, Roche, Otsuka Pharmaceutical and Prestwick Scientific Capital. She is cofounder and a managing member of KM Pharmaceutical Consulting in Washington, D.C.
  • Shawn Cross / President, COO
  • Steven W. Weldon / CFO
    • Mr. Weldon joined the GT Biopharma, lnc, Inc. team as a member of the Board of Directors in September . He was appointed Chief Financial Officer in November . Mr. Weldon was elected President of GT Biopharma, Inc. November , . Mr. Weldon is a certified public accountant licensed to practice in the state of Florida. Mr. Weldon has over years of financial and accounting experience with public and private companies. He most recently was the CFO of Grow BLOX GBLX . Steven received his Bachelor of Science degree and his Masters in Business Administration from Florida Southern College, where he was an adjunct professor. Mr. Weldon has years of experience as board member, Chief Financial Officer and Chief Executive Officer of publicly traded companies.
  • Raymond Urbanski / CMO
    • Dr. Urbanski spent eight years with Pfizer and held several positions with the company, including Vice President/CMO of the Established Products Business Unit, senior medical director of oncology clinical R amp D, senior medical director of breast cancer products and medical director of diversified products. He brings extensive experience in developing and overseeing clinical studies, including phase b and phase studies including line extensions for sunitinib Sutent , exemestane Aromasin , irinotecan Camptosar , epirubicin Ellence , axitinib, IGF R inhibitor, and tremilimumab. In addition to his role with Pfizer, Dr. Urbanski served as Chief Medical Officer of Mylan Inc., Chief Medical Officer of Metabolex Inc., and Senior Director of US Medical Affairs for Aventis.
  • Shawn M. Cross / Chairman
  • Anthony Cataldo / Executive Chairman
    • Mr. Cataldo founded GT Biopharma Inc. upon joining the Board of Directors and subsequently Chairman and CEO in in July of , where he changed the Company s profile with the inclusion of oncology assets. From February to June Mr. Cataldo served as Founder and Chairman/CEO of Genesis Biopharma, Inc., now known as Iovance Biotherapeutics, Inc., IOVA . Mr. Cataldo created the highly successful IOVA/Genesis with the inclusion of assets acquired from the National Cancer Institute for the treatment of stage four melanoma. Mr. Cataldo has extensive experience in the biotechnology sector having served as Chairman/CEO of several biotech companies including: Calypte Biomedical Corporation, and Senetek, PLC.
  • Kathleen ClarenceSmith / Director
    • Dr. ClarenceSmith founded GTP in . Prior to founding GTP, she cofounded Chase Pharmaceuticals Corporation in Washington D.C. and served as Chairman of the company s Board from to . Chase Pharmaceuticals was acquired by Allergan, PLC AGN in for million together with potential addition payments of million based upon regulatory and commercial milestones. Dr. ClarenceSmith also held executive management positions with Sanofi, Roche, Otsuka Pharmaceutical and Prestwick Scientific Capital. She is cofounder and a managing member of KM Pharmaceutical Consulting in Washington, D.C.
  • Steven W. Weldon / Director
    • Mr. Weldon joined the GT Biopharma, lnc, Inc. team as a member of the Board of Directors in September . He was appointed Chief Financial Officer in November . Mr. Weldon was elected President of GT Biopharma, Inc. November , . Mr. Weldon is a certified public accountant licensed to practice in the state of Florida. Mr. Weldon has over years of financial and accounting experience with public and private companies. He most recently was the CFO of Grow BLOX GBLX . Steven received his Bachelor of Science degree and his Masters in Business Administration from Florida Southern College, where he was an adjunct professor. Mr. Weldon has years of experience as board member, Chief Financial Officer and Chief Executive Officer of publicly traded companies.

Current Share Structure

  • Market Cap: $82,592,578 - 03/21/2018
  • Authorized: 150,000,000 - 03/19/2018
  • Issue and Outstanding: 47,466,999 - 03/19/2018

 


Recent Filings from (OTC: GTBP)

Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 15 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 14 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 27 2018
Notice from the SEC of registration effectiveness
Filing Type: EFFECTFiling Source: edgar
Filing Date: March, 22 2018
Notice from the SEC of registration effectiveness
Filing Type: EFFECTFiling Source: edgar
Filing Date: March, 22 2018
Pre-effective amendment to an S-3 filing
Filing Type: S-3/AFiling Source: edgar
Filing Date: March, 21 2018
Pre-effective amendment to an S-3 filing
Filing Type: S-3/AFiling Source: edgar
Filing Date: March, 21 2018
Amendment to a previously filed 8-K
Filing Type: 8-K/AFiling Source: edgar
Filing Date: March, 15 2018
Pre-effective amendment to an S-3 filing
Filing Type: S-3/AFiling Source: edgar
Filing Date: March, 15 2018
Pre-effective amendment to an S-3 filing
Filing Type: S-3/AFiling Source: edgar
Filing Date: March, 15 2018

 

 


Daily Technical Chart for (OTC: GTBP)

Daily Technical Chart for (OTC: GTBP)


Stay tuned for daily updates and more on (OTC: GTBP)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: GTBP)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in GTBP is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of GTBP and does not buy, sell, or trade any shares of GTBP. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/